Alvaro Pacheco-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alvaro Pacheco-Silva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Niels Olsen Saraiva Câmara
Federal University of São Paulo
2 shared publications - Vinicius Andrade-Oliveira
Mucosal Health and Immunity Laboratory (MHIL), Center for Natural and Human Sciences (CCNH), Federal Universityof ABC (UFABC), Santo André, São Paulo, Brazil
2 shared publications - Ana Claudia Torrecilhas
Laboratório de Imunologia Celular e Bioquímica de Fungos e Protozoários, Departamento de Ciências Farmacêuticas, Instituto de Ciências Ambientais, Químicas e Farmacêuticas Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil
1 shared publication - Cristiane Naffah de Souza Breda
Departamento de Imunologia, USP, Avenida Prof. Lineu Prestes 1730, ICB IV, São Paulo 05508-000, Brazil
1 shared publication - Danilo Candido de Almeida
Universidade Federal de São Paulo
1 shared publication - Eliana Lima Faquim-Mauro
Laboratory of Immunopathology, Butantan Institute, Brazil
1 shared publication
Latest Publications
- Open Access
- 6 October 2025
- Published by MDPI AG in Preprints.org
Downregulation of Enteroendocrine Genes Predicts Survival in Colon Cancer: A Bioinformatics-Based Analysis
Colorectal cancer (CRC) is the fourth and the third most common and deadlycancer, respectively, worldwide. Even with alternative therapies, some patients do notrespond to treatment. Identifying modulations in the tumor microenvironment (TME) ofCRC is indeed a challenge due to the complex and dynamic nature of the TME. Theintestinal epithelial cells (IECs) are composed by different types of secretory-lineagecells, such as goblet, tuft, paneth and enteroendocrine cells (EECs). Yet, the relevanceof each subtype of secretory IEC in the tumor microenvironment is still a matter of debate.This study investigated the involvement of IECs in CRC through an integrativebioinformatics analysis using publicly available datasets from National Center forBiotechnology Information (NCBI) and The Cancer Genome Atlas Program (TCGA),encompassing both human and mouse CRC samples. Our findings reveal a CRC TMEfeatured by elevated expression levels of genes associated with WNT pathway activity.Remarkably, there was an increased expression of Paneth cell-associated markers andtranscription factors, such as WISP1, LYZ, SOX9, and DEFA1 while enteroendocrinecells-specific gene markers, such as GCG (encoding Glucagon like Peptide-1) andCHGA exhibited a significant downregulation in CRC tissue compared with health tissue.Gene ontology (GO) analysis showed a species-conserved downregulation inhormone/peptide secretion-related pathways of CRC in mouse and human. Of note,lower levels of GCG and CHGA correlated with reduced overall survival andchemotherapy-unresponsive patients. These results suggest that disruption of EECsignaling is a hallmark of CRC development and may hold prognostic and therapeuticvalue for treating CRC patients.
- 6 October 2025
- Published by MDPI AG in Preprints.org
Open AccessDownregulation of Enteroendocrine Genes Predicts Survival in Colon Cancer: A Bioinformatics-Based Analysis
Colorectal cancer (CRC) is the fourth and the third most common and deadlycancer, respectively, worldwide. Even with alternative therapies, some patients do notrespond to treatment. Identifying modulations in the tumor microenvironment (TME) ofCRC is indeed a challenge due to the complex and dynamic nature of the TME. Theintestinal epithelial cells (IECs) are composed by different types of secretory-lineagecells, such as goblet, tuft, paneth and enteroendocrine cells (EECs). Yet, the relevanceof each subtype of secretory IEC in the tumor microenvironment is still a matter of debate.This study investigated the involvement of IECs in CRC through an integrativebioinformatics analysis using publicly available datasets from National Center forBiotechnology Information (NCBI) and The Cancer Genome Atlas Program (TCGA),encompassing both human and mouse CRC samples. Our findings reveal a CRC TMEfeatured by elevated expression levels of genes associated with WNT pathway activity.Remarkably, there was an increased expression of Paneth cell-associated markers andtranscription factors, such as WISP1, LYZ, SOX9, and DEFA1 while enteroendocrinecells-specific gene markers, such as GCG (encoding Glucagon like Peptide-1) andCHGA exhibited a significant downregulation in CRC tissue compared with health tissue.Gene ontology (GO) analysis showed a species-conserved downregulation inhormone/peptide secretion-related pathways of CRC in mouse and human. Of note,lower levels of GCG and CHGA correlated with reduced overall survival andchemotherapy-unresponsive patients. These results suggest that disruption of EECsignaling is a hallmark of CRC development and may hold prognostic and therapeuticvalue for treating CRC patients.
- Open Access
Extracellular Vesicles isolated from Mesenchymal Stromal Cells Modulate CD4+ T Lymphocytes Toward a Regulatory Profile
Mesenchymal stromal cells (MSCs) can generate immunological tolerance due to their regulatory activity in many immune cells. Extracellular vesicles (EVs) release is a pivotal mechanism by which MSCs exert their actions. In this study, we evaluate whether mesenchymal stromal cell extracellular vesicles (MSC-EVs) can modulate T cell response. MSCs were expanded and EVs were obtained by differential ultracentrifugation of the supernatant. The incorporation of MSC-EVs by T cells was detected by confocal microscopy. Expression of surface markers was detected by flow cytometry or CytoFLEX and cytokines were detected by RT-PCR, FACS and confocal microscopy and a miRNA PCR array was performed. We demonstrated that MSC-EVs were incorporated by lymphocytes in vitro and decreased T cell proliferation and Th1 differentiation. Interestingly, in Th1 polarization, MSC-EVs increased Foxp3 expression and generated a subpopulation of IFN-γ+/Foxp3+T cells with suppressive capacity. A differential expression profile of miRNAs in MSC-EVs-treated Th1 cells was seen, and also a modulation of one of their target genes, TGFbR2. MSC-EVs altered the metabolism of Th1-differentiated T cells, suggesting the involvement of the TGF-β pathway in this metabolic modulation. The addition of MSC-EVs in vivo, in an OVA immunization model, generated cells Foxp3+. Thus, our findings suggest that MSC-EVs are able to specifically modulate activated T cells at an alternative regulatory profile by miRNAs and metabolism shifting.
Open AccessExtracellular Vesicles isolated from Mesenchymal Stromal Cells Modulate CD4+ T Lymphocytes Toward a Regulatory Profile
Mesenchymal stromal cells (MSCs) can generate immunological tolerance due to their regulatory activity in many immune cells. Extracellular vesicles (EVs) release is a pivotal mechanism by which MSCs exert their actions. In this study, we evaluate whether mesenchymal stromal cell extracellular vesicles (MSC-EVs) can modulate T cell response. MSCs were expanded and EVs were obtained by differential ultracentrifugation of the supernatant. The incorporation of MSC-EVs by T cells was detected by confocal microscopy. Expression of surface markers was detected by flow cytometry or CytoFLEX and cytokines were detected by RT-PCR, FACS and confocal microscopy and a miRNA PCR array was performed. We demonstrated that MSC-EVs were incorporated by lymphocytes in vitro and decreased T cell proliferation and Th1 differentiation. Interestingly, in Th1 polarization, MSC-EVs increased Foxp3 expression and generated a subpopulation of IFN-γ+/Foxp3+T cells with suppressive capacity. A differential expression profile of miRNAs in MSC-EVs-treated Th1 cells was seen, and also a modulation of one of their target genes, TGFbR2. MSC-EVs altered the metabolism of Th1-differentiated T cells, suggesting the involvement of the TGF-β pathway in this metabolic modulation. The addition of MSC-EVs in vivo, in an OVA immunization model, generated cells Foxp3+. Thus, our findings suggest that MSC-EVs are able to specifically modulate activated T cells at an alternative regulatory profile by miRNAs and metabolism shifting.